Treatment strategies targeting the phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin pathway against triple-negative breast cancer

Table 4 Ongoing clinical trials associated with the phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin pathway in triple negative breast cancer

Inhibitors class	Trial code	Trial content	Trial period
mTOR inhibitors	NCT02616848	A phase I clinical trial to evaluate the efficacy and safety of everolimus in combination with arebuline for previously treated mTNBC	I
Pan-PI3K inhibitors	NCT01790932	A phase II clinical trial evaluating the efficacy of monotherapy with buparlisib (BKM120) in patients with TNBC	II
Pan-PI3K inhibitors	NCT01629615	A phase II clinical trial evaluating the efficacy of monotherapy with buparlisib in patients with TNBC	II
PI3K inhibitors	NCT02389842	A phase Ib clinical trial assessing the efficacy and safety of taselisib, a beta-preserving PI3K inhibitor, in combination with palbociclib for metastatic breast cancer, including those with TNBC	Ib
PI3K inhibitors	NCT03207529	A phase I clinical trial evaluating the combination of alpelisib, an alpha-specific PI3K inhibitor, with enzalutamide in patients with AR+ and PTEN+ breast cancer, including those with TNBC	I
AKT inhibitors	NCT02576444	A phase II clinical trial investigated various combinations of olaparib, specifically focusing on patients with breast cancer who received both olaparib and capivasertib	II
AKT inhibitors	CAPITELLO290	A clinical trial of the capivasertib in combination with paclitaxel for first-line treatment in patients with locally advanced or metastatic TNBC, included evaluating OS in subgroups whose tumors harbored PIK3CA, AKT1, or PTEN biomarker alterations	III

PI3K: Phosphoinositide 3-kinase; AKT: Protein kinase B; mTOR: Mechanistic target of rapamycin; mTNBC: Metastatic triple-negative breast cancer; TNBC: Triple negative breast cancer; PTEN: Phosphatase and tensin homolog; AR: Androgen receptor; OS: Overall survival; PIK3CA: Phosphoinositide3 kinase-alpha.